# Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

> **NCT04649411** · PHASE3 · WITHDRAWN · sponsor: **Keryx Biopharmaceuticals**

## Conditions studied

- Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** ferric citrate
- **DRUG:** standard of care

## Key facts

- **NCT ID:** NCT04649411
- **Lead sponsor:** Keryx Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PMR release
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649411, "Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04649411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*